Investigating how ATRX mutations affect immune response and treatment options in brain tumors.
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
This study is looking at how changes in a specific gene called ATRX might affect the immune system's ability to fight gliomas, which are harmful brain tumors, to find new ways to treat them better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10911273 on NIH RePORTER |
What this research studies
This research focuses on gliomas, a type of malignant brain tumor, and aims to understand how mutations in the ATRX gene influence the immune response within these tumors. By examining the relationship between ATRX mutations and immune cell activity, the study seeks to identify potential vulnerabilities that could be targeted for new therapies. The researchers will explore how these mutations may enhance inflammation and make tumors more susceptible to certain immune-based treatments. This approach could lead to improved strategies for managing gliomas and enhancing patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with gliomas, particularly those with ATRX mutations.
Not a fit: Patients with gliomas who do not have ATRX mutations may not benefit from the specific findings of this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with gliomas, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting immune responses in gliomas, but this specific approach focusing on ATRX mutations is relatively novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Ashley, David M. — Duke University
- Study coordinator: Ashley, David M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.